title: Cysteine-rich domain of scavenger receptor AI modulates the efficacy of surface targeting and mediates oligomeric Aβ internalization.
abstract: BACKGROUND
  Insufficient clearance of soluble oligomeric amyloid-β peptide (oAβ) in the central nervous system leads to the synaptic and memory deficits in Alzheimer's disease (AD). Previously we have identified scavenger receptor class A (SR-A) of microglia mediates oligomeric amyloid-β peptide (oAβ) internalization by siRNA approach. SR-A is a member of cysteine-rich domain (SRCR) superfamily which contains proteins actively modulating the innate immunity and host defense, however the functions of the SRCR domain remain unclear. Whether the SRCR domain of SR-AI modulates the receptor surface targeting and ligand internalization was investigated by expressing truncated SR-A variants in COS-7 cells. Surface targeting of SR-A variants was examined by live immunostaining and surface biotinylation assays. Transfected COS-7 cells were incubated with fluorescent oAβ and acetylated LDL (AcLDL) to assess their ligand-internalization capabilities.
  
  
  RESULTS
  Genetic ablation of SR-A attenuated the internalization of oAβ and AcLDL by microglia. Half of oAβ-containing endocytic vesicles was SR-A positive in both microglia and macrophages. Clathrin and dynamin in SR-AI-mediated oAβ internalization were involved. The SRCR domain of SR-AI is encoded by exons 10 and 11. SR-A variants with truncated exon 11 were intracellularly retained, whereas SR-A variants with further truncations into exon 10 were surface-targeted. The fusion of exon 11 to the surface-targeted SR-A variant lacking the SRCR domain resulted in the intracellular retention and the co-immunoprecipitation of Bip chaperon of the endoplasmic reticulum. Surface-targeted variants were N-glycosylated, whereas intracellularly-retained variants retained in high-mannose states. In addition to the collagenous domain, the SRCR domain is a functional binding domain for oAβ and AcLDL. Our data suggest that inefficient folding of SR-AI variants with truncated SRCR domain was recognized by the endoplasmic reticulum associated degradation which leads to the immature N- glycosylation and intracellular retention.
  
  
  CONCLUSIONS
  The novel functions of the SRCR domain on regulating the efficacy of receptor trafficking and ligand binding may lead to possible approaches on modulating the innate immunity in Alzheimer's disease and atherosclerosis.
authors.affiliation: Institute of Anatomy and Cell Biology, National Yang-Ming University, Taipei11221, Taiwan.
authors.forename: Fong-Lee
authors.initials: FL
authors.lastname: Huang
authors.forename: Young-Ji
authors.initials: YJ
authors.lastname: Shiao
authors.forename: Sheue-Jane
authors.initials: SJ
authors.lastname: Hou
authors.forename: Cheng-Ning
authors.initials: CN
authors.lastname: Yang
authors.forename: Yi-Jen
authors.initials: YJ
authors.lastname: Chen
authors.forename: Chao-Hsiung
authors.initials: CH
authors.lastname: Lin
authors.forename: Feng-Shiun
authors.initials: FS
authors.lastname: Shie
authors.forename: Huey-Jen
authors.initials: HJ
authors.lastname: Tsay
mesh_terms: D000544:Alzheimer Disease / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D019556:COS Cells; D002522:Chlorocebus aethiops; D003545:Cysteine / Q000235:genetics; D003593:Cytoplasm / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008077:Lipoproteins, LDL / Q000235:genetics / Q000378:metabolism; D017510:Protein Folding; D017434:Protein Structure, Tertiary; D059748:Proteolysis; D051117:Scavenger Receptors, Class A / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D013499:Surface Properties
chemical_list: D016229:Amyloid beta-Peptides; D008077:Lipoproteins, LDL; D051117:Scavenger Receptors, Class A; C032629:acetyl-LDL; D003545:Cysteine
references.citation: J Biol Chem. 2004 Dec 3;279(49):51561-7
references.pmid: 15448162
references.citation: Immunol Rev. 2009 Jan;227(1):19-31
references.pmid: 19120472
references.citation: J Immunol. 2008 Nov 1;181(9):6503-13
references.pmid: 18941241
references.citation: J Pept Sci. 2004 May;10(5):229-48
references.pmid: 15160835
references.citation: Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12
references.pmid: 17245412
references.citation: Atherosclerosis. 2001 Feb 1;154(2):415-9
references.pmid: 11166774
references.citation: Nat Rev Mol Cell Biol. 2004 Feb;5(2):133-47
references.pmid: 15040446
references.citation: Nature. 1990 Feb 8;343(6258):570-2
references.pmid: 2300208
references.citation: Physiol Rev. 2007 Oct;87(4):1377-408
references.pmid: 17928587
references.citation: J Mol Biol. 2006 Feb 17;356(2):469-82
references.pmid: 16376939
references.citation: J Leukoc Biol. 2010 Mar;87(3):443-9
references.pmid: 19952357
references.citation: J Biol Chem. 2002 Aug 30;277(35):32046-53
references.pmid: 12058030
references.citation: J Lipid Res. 2005 Jan;46(1):11-20
references.pmid: 15548472
references.citation: J Lipid Res. 2002 Nov;43(11):1829-36
references.pmid: 12401881
references.citation: Innate Immun. 2013 Feb;19(1):30-41
references.pmid: 22751446
references.citation: Crit Rev Immunol. 2004;24(1):1-37
references.pmid: 14995912
references.citation: EMBO J. 2003 Nov 17;22(22):6127-36
references.pmid: 14609958
references.citation: Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1317-22
references.pmid: 16574888
references.citation: J Biol Chem. 2007 Jun 1;282(22):16654-66
references.pmid: 17405873
references.citation: J Biol Chem. 2003 Feb 28;278(9):6942-6
references.pmid: 12488451
references.citation: J Biol Chem. 2011 May 27;286(21):18795-806
references.pmid: 21460221
references.citation: Cardiovasc Res. 2010 Dec 1;88(3):415-23
references.pmid: 20615914
references.citation: Biochem Biophys Res Commun. 2002 Feb 8;290(5):1462-9
references.pmid: 11820786
references.citation: J Immunol. 2011 Feb 15;186(4):2344-54
references.pmid: 21217009
references.citation: J Biol Chem. 1993 Jan 25;268(3):2126-33
references.pmid: 8380589
references.citation: Biol Pharm Bull. 1999 Oct;22(10):1022-6
references.pmid: 10549849
references.citation: Mol Cell Biol. 2005 Nov;25(22):9793-805
references.pmid: 16260597
references.citation: Circulation. 2008 Nov 18;118(21):2174-82
references.pmid: 18981301
references.citation: J Biol Chem. 2005 Oct 21;280(42):35391-8
references.pmid: 16030018
references.citation: Neurobiol Dis. 2011 Jun;42(3):221-30
references.pmid: 21220023
references.citation: J Biol Chem. 1998 Jul 31;273(31):19592-601
references.pmid: 9677385
references.citation: J Lipid Res. 2009 Apr;50 Suppl:S282-6
references.pmid: 19074372
references.citation: Mol Cell. 2005 Nov 23;20(4):503-12
references.pmid: 16307915
references.citation: J Lipid Res. 1998 Mar;39(3):531-43
references.pmid: 9548586
references.citation: Clin Chem. 2010 Mar;56(3):478-81
references.pmid: 20075180
references.citation: Nature. 2009 Feb 26;457(7233):1128-32
references.pmid: 19242475
references.citation: J Biol Chem. 1996 Oct 25;271(43):26924-30
references.pmid: 8900177
references.citation: J Biol Chem. 2000 Apr 21;275(16):11672-7
references.pmid: 10766786
references.citation: Pharmacol Rev. 2011 Dec;63(4):967-1000
references.pmid: 21880988
references.citation: J Biol Chem. 2011 Feb 4;286(5):3693-706
references.pmid: 20971854